TherapeuticsMD (NASDAQ:TXMD) Earns Hold Rating from Analysts at StockNews.com

Equities researchers at StockNews.com began coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a report released on Tuesday. The firm set a “hold” rating on the stock.

TherapeuticsMD Trading Down 0.3 %

Shares of TXMD opened at $1.58 on Tuesday. TherapeuticsMD has a twelve month low of $1.43 and a twelve month high of $3.07. The business’s 50-day moving average price is $1.70 and its 200-day moving average price is $1.83.

TherapeuticsMD (NASDAQ:TXMD) last posted its earnings results on Monday, August 12th. The company reported ($0.09) earnings per share for the quarter. The company had revenue of $0.23 million for the quarter.

Institutional Investors Weigh In On TherapeuticsMD

A hedge fund recently bought a new stake in TherapeuticsMD stock. Prosperity Consulting Group LLC bought a new stake in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 24,500 shares of the company’s stock, valued at approximately $56,000. Prosperity Consulting Group LLC owned about 0.21% of TherapeuticsMD at the end of the most recent reporting period. 30.74% of the stock is currently owned by hedge funds and other institutional investors.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.